Patents by Inventor Eric LaCasse

Eric LaCasse has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
    Patent number: 8012944
    Abstract: The invention features methods, compositions, and kits for treating a patient having a proliferative disease.
    Type: Grant
    Filed: October 28, 2004
    Date of Patent: September 6, 2011
    Assignee: Pharmascience Inc.
    Inventors: Eric LaCasse, Daniel McManus, Jon P. Durkin
  • Antisense IAP nucleobase oligomers and uses thereof
    Patent number: 7638497
    Abstract: The present invention features nucleobase oligomers that hybridize to IAP polynucleotide, and methods for using them to enhance apoptosis and treat proliferative disorders.
    Type: Grant
    Filed: June 30, 2006
    Date of Patent: December 29, 2009
    Assignee: Aegera Therapeutics, Inc.
    Inventors: Eric LaCasse, Daniel McManus, Jon P. Durkin
  • Antisense IAP nucleobase oligomers and uses thereof
    Patent number: 7638620
    Abstract: The present invention features nucleobase oligomers that hybridize to IAP polynucleotides, and methods for using them to enhance apoptosis and treat proliferative diseases.
    Type: Grant
    Filed: June 8, 2006
    Date of Patent: December 29, 2009
    Assignee: Aegera Therapeutics, Inc.
    Inventors: Eric LaCasse, Daniel McManus, Jonathan P. Durkin
  • Antisense IAP oligonucleotides and uses thereof
    Patent number: 7294713
    Abstract: The present invention feature antisense IAP oligonucleotides and other negative regulators of the IAP anti-apoptotic pathway, and methods for using them to enhance apoptosis.
    Type: Grant
    Filed: August 7, 2003
    Date of Patent: November 13, 2007
    Assignee: Aegera Therapeutics Inc.
    Inventors: Robert G. Korneluk, Eric LaCasse, Stephen Baird, Martin Holcik, Sean Young
  • Antisense IAP nucleobase oligomers and uses thereof
    Publication number: 20070178064
    Abstract: The present invention features nucleobase oligomers that hybridize to IAP polynucleotides, and methods for using them to enhance apoptosis and treat proliferative diseases.
    Type: Application
    Filed: June 8, 2006
    Publication date: August 2, 2007
    Inventors: Eric LaCasse, Daniel McManus, Jonathan Durkin
  • Antisense IAP oligonucleotides and uses thereof
    Publication number: 20070142316
    Abstract: The present invention features antisense IAP oligonucleotides and other negative regulators of the IAP anti-apoptotic pathway, and methods for using them to enhance apoptosis.
    Type: Application
    Filed: December 18, 2006
    Publication date: June 21, 2007
    Inventors: Robert Korneluk, Eric LaCasse, Stephen Baird, Martin Holcik, Sean Young
  • Antisense IAP nucleobase oligomers and uses thereof
    Publication number: 20070135371
    Abstract: The present invention features nucleobase oligomers that hybridize to IAP polynucleotides, and methods for using them to enhance apoptosis.
    Type: Application
    Filed: October 26, 2006
    Publication date: June 14, 2007
    Inventors: Eric LaCasse, Daniel McManus, Jon Durkin, Robert Korneluk, Martin Holcik
  • Antisense IAP oligonucleotides and uses thereof
    Publication number: 20070123481
    Abstract: The present invention features antisense IAP oligonucleotides and other negative regulators of the IAP anti-apoptotic pathway, and methods for using them to enhance apoptosis.
    Type: Application
    Filed: June 30, 2006
    Publication date: May 31, 2007
    Inventors: Robert Korneluk, Eric LaCasse, Stephen Baird, Martin Holcik, Sean Young
  • Antisense IAP nucleobase oligomers and uses thereof
    Publication number: 20070049544
    Abstract: The present invention features nucleobase oligomers that hybridize to IAP polynucleotide, and methods for using them to enhance apoptosis and treat proliferative disorders.
    Type: Application
    Filed: June 30, 2006
    Publication date: March 1, 2007
    Inventors: Eric LaCasse, Daniel McManus, Jon Durkin
  • Antisense IAP nucleobase oligomers and uses thereof
    Publication number: 20070032445
    Abstract: The present invention features nucleobase oligomers that hybridize to IAP polynuclotides, and methods for using them to enhance apoptosis and treat proliferative diseases.
    Type: Application
    Filed: May 30, 2006
    Publication date: February 8, 2007
    Inventors: Eric LaCasse, Daniel McManus, Jon Durkin
  • Antisense IAP nucleobase oligomers and uses thereof
    Patent number: 7091333
    Abstract: The present invention features nucleobase oligomers that hybridize to IAP polynucleotides, and methods for using them to enhance apoptosis and treat proliferative diseases.
    Type: Grant
    Filed: March 27, 2003
    Date of Patent: August 15, 2006
    Assignee: Aegera Therapeutics, Inc.
    Inventors: Eric LaCasse, Daniel McManus, Jon P. Durkin
  • Method for treating inflammatory disorders
    Publication number: 20060123501
    Abstract: The invention features a method of treating an inflammatory disorder, such as sepsis, in a subject. The method involves administering to the subject an antagonist of cIAP2 expression and/or function, so that the disorder is treated.
    Type: Application
    Filed: December 2, 2005
    Publication date: June 8, 2006
    Inventors: Robert Korneluk, Martin Holcik, Damiano Conte, Charles Lefebvre, Eric LaCasse
  • IAP nucleobase oligomers and oligomeric complexes and uses thereof
    Publication number: 20050148535
    Abstract: The present invention provides nucleobase oligomers and oligomer complexes that inhibit expression of an IAP polypeptide, and methods for using them to induce apoptosis in a cell. The nucleobase oligomers and oligomer complexes of the present invention may also be used to form pharmaceutical compositions. The invention also features methods for enhancing apoptosis in a cell by administering a nucleobase oligomer or oligomer complex of the invention in combination with a chemotherapeutic or chemosensitizing agent.
    Type: Application
    Filed: October 28, 2004
    Publication date: July 7, 2005
    Inventors: Eric LaCasse, Daniel McManus
  • Methods and reagents for the treatment of proliferative diseases
    Publication number: 20050119217
    Abstract: The invention features methods, compositions, and kits for treating a patient having a proliferative disease.
    Type: Application
    Filed: October 28, 2004
    Publication date: June 2, 2005
    Inventors: Eric LaCasse, Daniel McManus, Jon Durkin
  • Antisense IAP oligonucleotides and uses thereof
    Publication number: 20040127694
    Abstract: The present invention feature antisense IAP oligonucleotides and other negative regulators of the IAP anti-apoptotic pathway, and methods for using them to enhance apoptosis.
    Type: Application
    Filed: August 7, 2003
    Publication date: July 1, 2004
    Inventors: Robert G. Komeluk, Eric LaCasse, Stephen Baird, Martin Holcik, Sean Young
  • Antisense IAP nucleic acids and uses thereof
    Patent number: 6673917
    Abstract: The present invention feature antisense IAP nucleic acids and other negative regulators of the IAP anti-apoptotic pathway, and methods for using them to enhance apoptosis.
    Type: Grant
    Filed: September 28, 2000
    Date of Patent: January 6, 2004
    Assignee: University of Ottawa
    Inventors: Robert G. Korneluk, Eric LaCasse, Stephen Baird, Martin Holcik, Sean Young
  • Antisense IAP nucleobase oligomers and uses thereof
    Publication number: 20030190659
    Abstract: The present invention features nucleobase oligomers that hybridize to IAP polynucleotides, and methods for using them to enhance apoptosis and treat proliferative diseases.
    Type: Application
    Filed: March 27, 2003
    Publication date: October 9, 2003
    Inventors: Eric LaCasse, Daniel McManus, Jonathan P. Durkin
  • Methods and reagents for peptide-BIR interaction screens
    Publication number: 20030157522
    Abstract: The invention features a substantially pure polypeptide having a length of less than 100 amino acids and capable of forming a complex with a polypeptide that includes a BIR domain. The invention also features displacement assays in which the ability of a candidate compound to disrupt the interaction between a BIR domain-containing polypeptide and a polypeptide of the invention is indicative of the ability of the candidate compound to modulate IAP biological activity.
    Type: Application
    Filed: November 12, 2002
    Publication date: August 21, 2003
    Inventors: Alain Boudreault, Robert G. Korneluk, Eric LaCasse, Peter Liston